To the Editor: Dr. Dismukes and his colleagues in the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group deserve warm congratulations for the successful completion of a very difficult study (Aug. 6 issue).* My only disappointment is that, in their effort to shorten the course of therapy, they did not investigate the efficacy of a relatively short course (3 to 4 weeks) of amphotericin B combined with a longer course of flucytosine (6 to 10 weeks). It seems reasonable to assume that the period of greatest danger for the development of resistance to flucytosine is early in. © 1988, Massachusetts Medical Society. All rights reserved.